12 Stocks with Best Earnings Growth for the Next 5 Years

Page 4 of 11

8. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 114

Return on Equity (TTM): 48.29%

On January 14, BMO Capital reaffirmed an ‘Outperform’ rating on Eli Lilly and Company (NYSE:LLY) with a price target of $1,200. Matching the consensus 1-year median target price, the stock has an upside potential of 16.36%. The firm remains confident in the company’s solid leadership position in the obesity treatment space and beyond for 2026 and the years ahead.

BMO Capital pointed out that growth and certainty for the company’s incretin business is backed by broadening access, the expected launch of orforglipron, and the company’s growing portfolio. While maintaining its leadership in the obesity market, Eli Lilly and Company (NYSE:LLY) also has a solid presence in other disease areas, particularly Lp(a), which contributes to its long-term growth outlook, the firm added.

Two days earlier, Eli Lilly and Company (NYSE:LLY) announced a partnership with NVIDIA to develop an AI co-innovation lab focused on pharmaceutical research. The leading entities plan to invest up to $1 billion in talent, infrastructure, and computing resources over a period of five years.

Eli Lilly and Company (NYSE:LLY) is an Indiana-based company that discovers, develops, and markets human pharmaceuticals. Founded in 1876, the company is committed to improving people’s lives around the globe.

Page 4 of 11